Evidence map›Paper›PMID 40983629›Full record

ArticleBritish journal of cancer2025

Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.

Hidetaka Kawamura, Michitaka Honda, Yujiro Nakayama, Koji Oba, Masaru Muto, Toru Aoyama, Mitsuro Kanda, Hiromichi Maeda, Shuhei Mayanagi, Kosuke Kashiwabara and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hidetaka KawamuraDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Koriyama-shi, Fukushima, Japan. hidetaka0716.hk@gmail.com.ORCID http://orcid.org/0000-0003-2396-0701
Michitaka HondaDepartment of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, Koriyama-shi, Fukushima, Japan.
Yujiro NakayamaFaculty of Medical Sciences, Shonan University of Medical Sciences, Yokohama-shi, Kanagawa, Japan.
Koji ObaInterfaculty Initiative in Information Studies, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Masaru MutoJapanese Foundation for Multidisciplinary Treatment of Cancer, Koto-ku, Tokyo, Japan.
Toru AoyamaDepartment of Gastric Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
Mitsuro KandaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya-shi, Aichi, Japan.ORCID http://orcid.org/0000-0001-5464-3819
Hiromichi MaedaDepartment of Surgery, Kochi University, Nankoku-shi, Kochi, Japan.
Shuhei MayanagiDivision of Esophageal Surgery, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan.ORCID http://orcid.org/0000-0002-0120-3497
Kosuke KashiwabaraData Science Office, Clinical Research Promotion Center, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Kenji TanakaInterfaculty Initiative in Information Studies, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Junichi SakamotoTokai Central Hospital, Kakamigahara-shi, Gifu, Japan.
Hisakazu YamagishiInterfaculty Initiative in Information Studies, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Takaki YoshikawaDepartment of Gastric Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdverse events during postoperative adjuvant chemotherapy may reflect prognosis in resectable advanced colorectal cancer. This study assessed the association between these events and survival in advanced colorectal cancer patients.

methodsWe analysed patient data from four Japanese randomised controlled trials on adjuvant chemotherapy for stage II or III colorectal cancer. Adverse events were defined as the maximum grade within 6 months. The primary outcome was overall survival, analysed using a multivariate-adjusted Cox proportional hazard model.

resultsA total of 4,046 patients with advanced colorectal cancer undergoing adjuvant chemotherapy were included. Maximum adverse event grades were: 739 (18%) grade 0, 960 (24%) grade 1, 1511 (37%) grade 2, 779 (19%) grade 3 and 57 (1.4%) grade 4. Compared to grade 0, hazard ratios for overall survival were 0.77 (95% CI, 0.61-0.98) for grade 1, 0.70 (95% CI, 0.56-0.87) for grade 2, 0.69 (95% CI, 0.53-0.91) for grade 3 and 1.12 (95% CI, 0.62-2.04) for grade 4.

conclusionsThe severity of adverse events during adjuvant chemotherapy correlated with survival outcomes in advanced colorectal cancer. Mild to moderate events were linked to improved prognosis, while absence suggested poorer outcomes, indicating a need for alternative treatments.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsAdultAgedChemotherapy, AdjuvantFemaleHumansJapanMaleMiddle AgedPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicTreatment Outcome

Identifiers

PMID40983629
PMCPMC12644743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.